Agomab Therapeutics NV (Nasdaq: AGMB) has announced the design of its NOV-ERA Phase 2b study evaluating ontunisertib in patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE